Explore more about Patient Reported Outcomes
HDx therapy enabled by Theranova dialyzer has shown improvements in patient reported outcomes including symptom burden, restless legs syndrome criteria, pruritus and dialysis recovery time.1, 2, 3
Importance of Patient-Reported Measures
The substantial increase of dialysis trials reveals inconsistent study design and reporting, making it more challenging to apply outcomes that improve the health and quality of life of dialysis patients. Without consistent trial parameters derived from research, clinical experience, and patient preferences, the needs of the patient and the option of better treatment outcomes will continue to remain in the background.4
Primary clinical studies illuminate the benefits of HDx therapy enabled by Theranova dialyzer
Lim JH et al. Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance hemodialysis patients.
Theranova dialyzer may improve patient-reported outcomes, particularly in the physical domains of QOL and uremic pruritus, through efficient removal of middle molecules, in stable maintenance HD patients.1
Alarcon JC, et al. Impact of Medium Cut-Off Dialyzers on Patient-Reported Outcomes (PROs): COREXH Registry.
Expanded clearance of middle molecular uremic toxins with Theranova dialyzer may improve patient-reported kidney disease quality of life outcomes including symptom burden, and Restless Legs Syndrome criteria.2
Bolton S et al. Clinical Assessment of Dialysis Recovery Time and Symptom Burden: Impact of Switching Hemodialysis Therapy Mode.
Sustained improvements in patient-reported post-dialysis recovery time and POS-S Renal fatigue score were observed over a 12-month period after a switch from regular HD/HDF using high-flux membranes to HDx therapy using the MCO membrane. Switching to HDx therapy with MCO membrane led to a sustained, clinically relevant decrease in patient-reported recovery time after dialysis and a decrease in fatigue levels.3
Penny JD et al. Impact of expanded hemodialysis using medium cut-off dialyzer on quality of life: application of dynamic patient-reported outcome measurement tool.
Patients with lower LEVIL scores (<70/100) at baseline showed improvement in overall HRQoL after 8 weeks of therapy with similar carryover effect. General well-being, energy, and sleep quality were improved significantly as a consequence of HDx therapy. There were no detrimental effects of HDx therapy detected in patients with higher baseline HRQoL.5
Reference Library
Hear from patients, nephrologists, and nurses alike share their experience prescribing HDx therapy. Be reassured by the pioneering commitment of Baxter to dialysis patients the world over and learn how Theranova dialyzers are made.
HDx Therapy Evidence Compendium
On-going research and clinical reporting are an integral part of the HDx therapy journey. Explore the the expanding evidence related to HDx therapy enabled by Theranova dialyzer that nephrologists around the world continue to generate.
HDx Therapy Brochure
Here you can find the HDx therapy brochure with more information about prescribing HDx therapy for your hemodialysis patients.
HDx Therapy Specification Sheets
Here you can find the detailed profiles of Theranova dialyzers.
Important Safety Information
Theranova dialyzers are indicated for treatment of chronic and acute renal failure by hemodialysis.
*Do not use Theranova dialyzers in HDF or HF mode.
For safe and proper use of this device, please refer to Instructions for Use.
